# A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

Study · id `cardio:ct-nct05618808` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05618808](<https://clinicaltrials.gov/study/NCT05618808>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05618808

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 373 participants.

## Technical summary

Registry record NCT05618808. Randomized; no masking; primary purpose treatment. Start 2023-05-24 (actual); primary completion 2024-05-27 (actual). Results posted on 2025-07-16.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 373 participants (enrolled count; ClinicalTrials.gov record NCT05618808, source copy `cardio:ctgov-nct05618808-2025-08-29`, retrieved 2026-10-31)
- Started: 2023-05-24 (actual) (ClinicalTrials.gov record NCT05618808, source copy `cardio:ctgov-nct05618808-2025-08-29`, retrieved 2026-10-31)
- Primary completion: 2024-05-27 (actual) (ClinicalTrials.gov record NCT05618808, source copy `cardio:ctgov-nct05618808-2025-08-29`, retrieved 2026-10-31)
- Completion: 2024-05-27 (actual) (ClinicalTrials.gov record NCT05618808, source copy `cardio:ctgov-nct05618808-2025-08-29`, retrieved 2026-10-31)
- Results first posted: 2025-07-16 (ClinicalTrials.gov record NCT05618808, source copy `cardio:ctgov-nct05618808-2025-08-29`, retrieved 2026-10-31)
- Countries: Belgium; Bulgaria; Canada; Hungary; Latvia; Lithuania; Poland (ClinicalTrials.gov record NCT05618808, source copy `cardio:ctgov-nct05618808-2025-08-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05618808-2025-08-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants
- Condition: Venous Thromboembolism
- Intervention (Drug): REGN9933
- Intervention (Drug): Enoxaparin
- Intervention (Drug): Apixiban
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry intervention name matches this record: Enoxaparin (`core:enoxaparin`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

## Provenance

Content hash: ad16755f2debb9efd5c6edd4c3a840e1956bc16ddd35ca2a902ad5240aa9f83d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
